The significance of serum levels of adiponectin, leptin, and hyaluronic acid in hepatocellular carcinoma of cirrhotic and noncirrhotic patients

Human and Experimental Toxicology

Volumn 31, Issue 4, 2012, Pages 311-321

  Sadik, N A H ^a   Ahmed, A ^b   Ahmed, S ^b  

^a CAIRO UNIVERSITY   (Egypt)

^b National Hepatology and Tropical Medicine Institute   (Egypt)

Author keywords

adiponectin; Hepatocellular carcinoma; hyaluronic acid; leptin

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; HYALURONIC ACID; LEPTIN; SCLEROPROTEIN;

ADIPOSE TISSUE; ADULT; ARTICLE; BLOOD LEVEL; CANCER PATIENT; CHRONIC HEPATITIS; CONTROLLED STUDY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY;

ADIPONECTIN; ADULT; AGED; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; FEMALE; HUMANS; HYALURONIC ACID; LEPTIN; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES;

EID: 84860453490     PISSN: 09603271     EISSN: 14770903     Source Type: Journal    
DOI: 10.1177/0960327111431091     Document Type: Article

References (55)

1. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003 ; 362: 1907-1917 (Pubitemid 37518510)
2. Parkin DM. The global health burden of infection- associated cancers in the year 2002. Int J Cancer. 2006 ; 118: 3030-3044
3. Ezzat S, Abdel-Hamid M, Eissa SA, Mokhtar N, Labib NA, El-Ghorory L, et al. Associations of pesticides, HCV, HBV, and hepatocellular carcinoma in Egypt. Int J Hyg Environ Health. 2005 ; 208: 329-339 (Pubitemid 41207425)
4. Deuffic-Burban S, Mohamed MK, Larouze B, Carrat F, Valleron AJ. Expected increase in hepatitis C-related mortality in Egypt due to pre-2000 infections. J Hepatol. 2006 ; 44 (3). 455-461 (Pubitemid 43227869)
5. Di Bisceglie AM, Lyra AC, Schwartz M, Reddy RK, Martin P, Gores G, et al. Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. Am J Gastroenterol. 2003 ; 98: 2060-2063 (Pubitemid 37185806)
6. Ikeda K, Saitoh S, Suzuki Y, Kobayashi M, Tsubota A, Koida I, et al. Disease progression and hepatocellular arcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. J Hepatol. 1998 ; 28: 930-938 (Pubitemid 28275969)
7. Marchesini G, Moscatiello S, Di Domizio S, Forlani G. Obesity-associated liver disease. J Clin Endocrinol Metab. 2008 ; 93: S74 - S80
8. Medina J, Arroyo AG, Sanchez-Madrid F, Moreno-Otero R. Angiogenesis in chronic inflammatory liver disease. Hepatology. 2004 ; 39: 1185-1195 (Pubitemid 38569038)
9. Marra F, Bertolani C. Adipokines in liver diseases. Hepatology. 2009 ; 50 (3). 957-969
10. Balmer ML, Joneli J, Schoepfer A, Stickel F, Thormann W, Dufour JF. Significance of serum adiponectin levels in patients with chronic liver disease. Clin Sci (Lond). 2010 ; 119 (10). 431-436
11. Diez JJ, Iglesias P. The role of the novel adipocyte- derived hormone adiponectin in human disease. Eur J Endocrinol. 2003 ; 148: 293-300 (Pubitemid 36410714)
12. Yoda-Murakami M, Taniguchi M, Takahashi K, Kawamata S, Saito K, Choi-Miura NH, et al. Change in expression of GBP28/adiponectin in carbon tetrachloride-administrated mouse liver. Biochem Biophys Res Commun. 2001 ; 285: 372-377 (Pubitemid 32918080)
13. Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature. 2003 ; 423: 762-769 (Pubitemid 36735700)
14. Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J.. Beyond insulin resistance in NASH: TNF-α or adiponectin?. Hepatology. 2004 ; 40: 46-54 (Pubitemid 38868922)
15. Kelesidis I, Kelesidis T, Mantzoros CS. Adiponectin and cancer: a systematic review. Br J Cancer. 2006 ; 4 (9). 1221-1225
16. Myers MG, Cowley MA, Munzberg H. Mechanisms of leptin action and leptin resistance. Annu Rev Physiol. 2008 ; 70: 537-556 (Pubitemid 351738191)
17. Meier U, Gressner AM. Endocrine regulation of energy metabolism: review of pathobiochemical and clinical chemical aspects of leptin, ghrelin, adiponectin, and resistin. Clin Chem. 2004 ; 50: 1511-1525 (Pubitemid 39121218)
18. Sierra-Honigmann MR, Nath AK, Murakami C, Garcia-Gardena G, Papapetropoulos A, Sessa WC, et al. Biological action of leptin as an angiogenic factor. Science. 1998 ; 281: 1683-1686 (Pubitemid 28435586)
19. Otero M, Lago R, Lago F, Casanueva FF, Dieguez C, Gomez-Reino JJ, et al. Leptin, from fat to inflammation:old questions and new insights. FEBS Lett. 2005 ; 579: 295-301 (Pubitemid 40092403)
20. Caldefie-Chézet F, Damez M, de Latour M, Konska G, Mishellani F, Fusillier C, et al. Leptin: a proliferative factor for breast cancer? Study on human ductal carcinoma. Biochem Biophys Res Commun. 2005 ; 334: 737-741 (Pubitemid 41033183)
21. Wang XJ, Yuan SL, Lu Q, Lu YR, Zhang J, Liu Y, et al. Potential involvement of leptin in carcinogenesis of hepatocellular carcinoma. World J Gastroenterol. 2004 ; 10 (17). 2478-2481 (Pubitemid 39206763)
22. Saxena NK, Sharma D, Ding X, Lin S, Marra F, Merlin D, et al. Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells. Cancer Res. 2007 ; 67: 2497-2507 (Pubitemid 46548934)
23. Fava G, Alpini G, Rychlicki C, Saccomanno S, DeMorrow S, Trozzi L, et al. Leptin enhances cholangiocarcinoma cell growth. Cancer Res. 2008 ; 68: 6752-6761
24. Ramani K, Yang H, Xia M, Ara AI, Mato JM, Lu SC. Leptin's mitogenic effect in human liver cancer cells requires induction of both methionine adenosyltransferase 2A and 2beta. Hepetology. 2008 ; 47: 521-531 (Pubitemid 351280720)
25. Stefanou N, Papanikolaou V, Furukawa Y, Nakamura Y, Tsezou A. Leptin as a critical regulator of hepatocellular carcinoma development through modulation of human telomerase reverse transcriptase. BMC Cancer. 2010 ; 442: 10
26. Zhang L, Underhill CB, Chen L. Hyaluronan on the surface of tumor cells is correlated with metastatic behavior. Cancer Res. 1995 ; 55: 428-433
27. Kojima J, Nakamura N, Kanatani M, Omori K. The glycosaminoglycans in human hepatic cancer. Cancer Res. 1975 ; 35: 542-547
28. Horai T, Nakamura N, Tateishi R, Hattori S. Glycosaminoglycans in human lung cancer. Cancer. 1981 ; 48: 2016-2021 (Pubitemid 12231556)
29. Fries H, Elsasser HP, Mahlbacher V, Neumann K, Kern HF. Localization of hyaluronate (HA) in primary tumors and nude mouse xenografts of human pancreatic carcinomas using a biotinylated HA-binding protein. Virchows Archiv. 1994 ; 424: 7-12 (Pubitemid 24102376)
30. Dahl IM, Turesson I, Holmberg E, Lilja K. Serum hyaluronan in patients with multiple myeloma: correlation with survival and Ig concentration. Blood. 1999 ; 93: 4144-4148 (Pubitemid 29279256)
31. Delpech B, Chevallier B, Reinhardt N, Julien JP, Duval C, Maingonnat C, et al. Serum hyaluronan (hyaluronic acid) in breast cancer patients. Int J Cancer. 1990 ; 46 (3). 388-390 (Pubitemid 20291090)
32. Hautmann SH, Schroeder GL, Civantos F, Duncan RC, Gnann R, Friedrich MG, et al. Hyaluronic acid and hyaluronidase. 2 new bladder carcinoma markers. Urologe A. 2001 ; 40: 121-126 (Pubitemid 32233336)
33. Hiltunen EL, Anttila M, Kultti A, Ropponen K, Penttinen J, Yliskoski M, et al. Elevated hyaluronan concentration without hyaluronidase activation in malignant epithelial ovarian tumors. Cancer Res. 2002 ; 62: 6410-6413 (Pubitemid 35364096)
34. Xing RD, Chang SM, Li JH, Li H, Han ZX. Serum hyaluronan levels in oral cancer patients. Chin Med J (Engl). 2008 ; 121 (4). 327-330 (Pubitemid 351479649)
35. Guo LX, Zou K, Ju JH, Xie H. Hyaluronan promotes tumor lymphangiogenesis and intralymphantic tumor growth in xenografts. Acta Biochim Biophys Sin (Shanghai). 2005 ; 37 (9). 601-606 (Pubitemid 43002364)
36. Yarasheski KE, Zachwieja JJ, Horgan MM, Powderly WG, Santiago JV, Landt M. Serum leptin concentrations in human immunodeficiency virus-infected men with low adiposity. Metabolism. 1997 ; 46 (3). 303-305 (Pubitemid 27106789)
37. Tacke F, Wüstefeld T, Horn R, Luedde T, Srinivas Rao A, Manns MP, et al. High adiponectin in chronic liver disease and cholestasis suggests biliary route of adiponectin excretion in vivo. J Hepatol. 2005 ; 42 (5). 666-673
38. Tietge UJ, Böker KH, Manns MP, Bahr MJ. Elevated circulating adiponectin levels in liver cirrhosis are associated with reduced liver function and altered hepatic hemodynamics. Am J Physiol Endocrinol Metab. 2004 ; 287 (1). E82 - E89
39. Okamoto Y, Arita Y, Nishida M, Muraguchi M, Ouchi N, Takahashi M, et al. An adipocyte-derived plasma protein, adiponectin, adheres to injured vascular walls. Horm. Metab Res. 2000 ; 32: 47-50 (Pubitemid 30143606)
40. Ouchi N, Kihara S, Arita Y, Okamoto Y, Maeda K, Kuriyama H, et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kB signaling through a cAMP-dependent pathway. Circulation. 2000 ; 102: 1296-1301
41. Suba Z, Ujpál M. Correlations of insulin resistance and neoplasms. Magy Onkol. 2006 ; 50 (2). 127-135
42. Di Bisceglie AM, Hoofnagle JH. Elevations in serum alphafetoprotein levels in patients with chronic hepatitis B. Cancer. 1989 ; 64: 2117-2120 (Pubitemid 19280413)
43. Cheema AW, Hirschtritt T, Van Thiel DH. Markedly elevated alpha-fetoprotein levels without hepatocellular carcinoma. Hepatogastroenterology. 2004 ; 51: 1676-1678 (Pubitemid 39389757)
44. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference, European Association for the Study of the Liver. J Hepatol. 2001 ; 35: 421-430 (Pubitemid 32844200)
45. Luo K, Liu Z, Karayiannis P. Effect of antiviral treatment on alfa-fetoprotein levels in HBV-related cirrhotic patients: early detection of hepatocellular carcinoma. J Viral Hepat. 2010 ; 17 (7). 511-517
46. Wang YY, Lin SY. Leptin in relation to hepatocellular carcinoma in patients with liver cirrhosis. Horm Res. 2003 ; 60: 185-190
47. Engström-Laurent A, Lööf L, Nyberg A, Schröder T. Increased serum levels of hyaluronate in liver disease. Hepatology. 1985 ; 5 (4). 638-642 (Pubitemid 15029737)
48. Ueno T, Inuzuka S, Sata M, Koh H, Tamaki S, Kin M, et al. Serum hyaluronate predicts response to interferon-alpha therapy in patients with chronic hepatitis C. Hepatogastroenterology. 1995 ; 42 (5). 522-527 (Pubitemid 3007994)
49. Tran A, Hastier P, Barjoan EM, Demuth N, Pradier C, Saint-Paul MC, et al. Non invasive prediction of severe fibrosis in patients with alcoholic liver disease. Gastroenterol Clin Biol. 2000 ; 24 ((6-7)). 626-630 (Pubitemid 30636794)
50. Plevris JN, Haydon GH, Simpson KJ, Dawkes R, Ludlum CA, Harrison DJ. Serum hyaluronan-a non-invasive test for diagnosing liver cirrhosis. Eur J Gastroenterol Hepatol. 2000 ; 10: 1121-1127
51. Kumar S, West DC, Ponting JM, Gattamaneni HR. Sera of children with renal tumours contain low-molecular-mass hyaluronic acid. Int J Cancer. 1989 ; 44: 445-448 (Pubitemid 19229301)
52. Bharadwaj AG, Kovar JL, Loughman E, Elowsky C, Oakley GG, Simpson MA. Spontaneous metastasis of prostate cancer is promoted by excess hyaluronan synthesis and processing. Am J Pathol. 2009 ; 174 (3). 1027-1036
53. Ghatak S, Misra S, Toole BP. Hyaluronan oligosaccharides inhibit anchorage-independent growth of tumor cells by suppressing the phosphoinositide 3-kinase/Akt cell survival pathway. Biol Chem. 2002 ; 277 (41). 38013-38020 (Pubitemid 35154652)
54. Danen EH, Yamada KM. Fibronectin, integrins, and growth control. J Cell Physiol. 2001 ; 189 (1). 1-13
55. Lokeshwar VB, Obek C, Pham HT, Wei D, Young MJ, Duncan RC, et al. Urinary hyaluronic acid and hyaluronidase: markers for bladder cancer detection and evaluation of grade. J Urol. 2000 ; 163 (1). 348-356